On July 16, we noted, “Apple looks interesting. Last trading at $210.40, we’d like to see the tech giant break above triple top resistance with a near-term bearish gap refill at around $220. Helping, analysts at Jefferies just raised their price target on Apple to $188.32 from $170.62. The firm is still positive about the strength of Apple’s sales in the June 2025 quarter.”

Today, Apple is up to $232.70 and could push even higher. Helping, analysts at BTIG just reiterated a buy rating on the stock with a $198 price target. This was after Apple announced it would reintroduce its Blood Oxygen feature for certain Apple Watch models. 

As noted by Investing.com, “The original Blood Oxygen feature was disabled following an International Trade Commission ruling that took effect in late 2023. In January 2024, U.S. Customs and Border Protection permitted Apple to sell its Apple Watch Series 9 and Ultra 2 with a software workaround that excluded the pulse oximeter function.”

Apple is also releasing other new and updated AI-powered devices, including robots, a smart speaker with display and security cameras, and an updated “lifelike” Siri capable of communicating with several users at once, as noted by Bloomberg.

Sincerely,

Ian Cooper